Boehringer Ingelheim Pharma Gmbh & Co Kg

Florian Colbatzky

Matthias Grauert

Flavio Solca

Martin Steegmaier

Anke Baum

Matthias Hoffmann

Gisela Schnapp

Norbert Hauel

Christian Eickmeier

Steffen Breitfelder

Trixi Brandl

Jens Juergen Quant

Ulrich Busch

Jens Jurgen Quant

Armin Heckel

Gerald Juergen Roth

Rudolf Hauptmann

Rainer Walter

Frank Hilberg

Matthias Hoffman

Steffan Ernest

Martin Fredrich Stefanic

Stefan Platz

Thomas Singer

Martin Friedrich Stefanic

Steffen Ernst

Gerald Jürgen Roth

The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy

Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

Dihydropteridinone compounds

The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.

Use of Lck inhibitors for treatment of immunologic diseases

Methods for treating diseases or conditions using dihydropteridinone compounds

Disclosed are dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and specification, the pharmaceutical compositions, isomers, intermediates thereof and processes for preparing these dihydropteridinones. The compounds are useful the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.

Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same

The present invention relates to new compounds of general formula having thrombin-inhibiting activity. Exemplary are:

Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide

The present invention relates to new compounds of general formulahaving thrombin-inhibiting activity. Exemplary are:

The present invention relates to new dihydropteridinones of general formula (I):wherein the groups L and R-Rhave the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions

Growing community of inventors

Stafflangen, Germany

Florian Colbatzky